Jim Xiao

7PUBLICATIONS
10CO-AUTHORS
Molecular targetsPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 14, 2026
Discovery of NKT2152, a Potent and Selective HIF-2α Inhibitor with Favorable Pharmacokinetic Properties.

|Sep 15, 2022
Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.

Mingxiang Liao, Jeri Beltman, Heidi Giordano

|Jul 17, 2022
Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer.

Mingxiang Liao, Jie Zhou, Kenton Wride

|Apr 10, 2022
Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.

Michelle L Green, Shu Chin Ma, Sandra Goble

|Aug 09, 2021
A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.

Mingxiang Liao, Krzysztof G Jeziorski, Monika Tomaszewska-Kiecana

|Apr 28, 2021
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.

Nikolay Grechko, Viera Skarbova, Monika Tomaszewska-Kiecana

Pageof 2

Frequent Collaborators

2 joint publications

Mingxiang Liao

1 joint publications

Michelle L Green

1 joint publications

Monika Tomaszewska-Kiecana

1 joint publications

Rodryg Ramlau